Published in AIDS Vaccine Week, March 28th, 2005
For the 4th quarter of 2004, Vitex reported a net loss of $7.2 million or $0.13 per share versus a net loss of $2.7 million or $0.07 per share for the 4th quarter of 2003. Revenue from research funding increased from $0.4 million in the 4th quarter of 2003 to $1.2 million in the 4th quarter of 2004, reflecting the recognition into revenue of approximately $0.8 million in previously deferred revenue relating to nonrefundable up-front and milestone payments from Amersham Pharmacia...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.